安科生物(300009.SZ)：签署PA3-17注射液产品独家代理框架协议

Core Viewpoint - Anke Biotechnology has entered into a strategic cooperation with its affiliate, Boshengji Pharmaceutical Technology, to exclusively promote and sell the PA3-17 injection product in Greater China after its market launch [1][2]. Group 1: Strategic Cooperation - Anke Biotechnology and Boshengji Pharmaceutical signed a framework agreement for exclusive agency rights concerning the PA3-17 injection product in Greater China, effective November 11, 2025 [1]. - The agreement outlines the responsibilities for sales and promotion of the PA3-17 injection product once it is launched [1]. Group 2: Product Details - PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, developed by Boshengji's subsidiary [2]. - The initial indication for PA3-17 is for the treatment of adult relapsed and refractory CD7-positive hematologic malignancies [2]. - The product has been included in the list of breakthrough therapies by the National Medical Products Administration and has entered a critical Phase II clinical trial [2]. Group 3: Future Collaboration - Boshengji has committed to prioritizing Anke Biotechnology as the exclusive agency for future product launches, ensuring long-term collaboration for sales and promotion [2].